Clinical trial NCT01676298: Spartan FRX Project Reproducibility Study
Official title: Study of the Analytical Reproducibility of the Spartan FRX CYP2C19 *2,*3 and *17 Genotyping System.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Analytical Reproducibility of a Medical Device
Keywords: Cyp2C19
Genotyping
Spartan
Reproducibility
Lead sponsor: Spartan Bioscience Inc.
Sponsor class: INDUSTRY
Collaborators: name: Children's Hospital of Eastern Ontario
name: Ottawa Hospital Research Institute
name: Mount Sinai Hospital, Canada
First posted: 2012-08-30
Enrollment: 8
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 8 Individuals with predetermined CYP2C19 \*2,\*3 and \*17 genotypes

Brief summary: The Spartan FRX CYP2C19 Test System (hereafter referred to as the 'FRX System') is a qualitative in vitro diagnostic test for the identification of a patient's CYP2C19 \*2, \*3 and \*17 genotypes from genomic DNA obtained from buccal swab samples. The objective of the study is to evaluate the performance of the FRX System under multivariate conditions including different days, sites, operators and systems.

Detailed description: The FRX system is comprised of hardware and consumable components. The hardware components of the system include an Analyzer (thermal cycler with fluorescence detection capability), a notebook computer and a printer. The consumable component of the FRX system is a sample collection kit. Each kit contains a buccal swab (used to collect the patient sample) and a tube containing the reagents required for genomic DNA extraction and PCR (polymerase chain reaction) amplification stages of the test.

The Spartan FRX System is capable of detecting three CYP2C19 SNPs(single nucleotide polymorphism) (\*2, \*3, \*17) in each test performed. An individual sample collection kit is required for each SNP tested; therefore three sample collection kits are required for each test performed on the system.

To perform a test, the user collects three buccal samples from the patient and then inserts a sample into each of the three reagent tubes (one for each of the CYP2C19 loci \*2, \*3 and \*17). The reagent tubes are placed into the Analyzer and the FRX system automates the processes of DNA extraction, PCR amplification, fluorescent signal detection and data analysis. The system provides the user with a printed result listing the patient genotypes at the \*2, \*3 and \*17 loci.

The objective of the study is to evaluate the performance of the FRX System under multivariate conditions. Specifically, the following variables will be included in the study:

* Test site - x3
* Operator - x6 (2 per site)
* Day - x15 (5 non-consecutive days per site)
* FRX System - x16

Test performance is defined as the number of correct genotype calls, expressed as a percentage of the total number of tests performed on the system.

For both the first-pass and second-pass results, 1-sided 95% confidence lower limits will be calculated using the score method for the % correct calls (i.e. % agreement).

Genotype results from the FRX system will be compared with results of DNA sequencing. The result of the FRX System test will be determined to be correct if the genotype calls for all three SNPs are identical to the genotypes determined by DNA sequencing for that sample/individual.

Results of the Reproducibility Study will be acceptable if the lower bound of a 1-sided 95% confidence limit of the total correct call rate per genotype is greater than or equal to 95%, based on second-pass results.

Eligibility criteria: Inclusion Criteria:

* Above 16 years of age
* Must have required genotype

Exclusion Criteria:

* None

Primary outcomes:
measure: Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System.
timeFrame: After second pass result is complete (~3h)
Secondary outcomes:
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: Children's Hospital of Eastern Ontario
state: Ontario
city: Ottawa
country: Canada
facility: Ottawa Hospital Research Institute
state: Ontario
city: Toronto
country: Canada
facility: Mount Sinai Services
state: Ontario
Study officials:
affiliation: Spartan Bioscience
name: Chris JE Harder, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: MOUNT SINAI HOSPITAL
name: Azar Azad, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ottawa Hosptial Research Institute
name: Marc Desjardins, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Children's Hospital of Eastern Ontario
name: Jean McGowan-Jordan, PhD
role: PRINCIPAL_INVESTIGATOR
References: